ABVC BioPharma Seeks to Revolutionize Mental Health Treatment With a Safe Prozac Alternative, Boasting a MADRS Score Reduction of -13.21
ABVC BioPharma's New Treatment: ABVC BioPharma is developing ABV-1504, a treatment derived from Radix Polygala, as a safer alternative for Major Depressive Disorder (MDD) and ADHD following the discontinuation of Prozac due to side effect concerns. The drug has completed Phase II trials and is moving towards Phase III.
Market Growth Potential: The global markets for MDD and ADHD treatments are projected to grow significantly, with MDD expected to reach $14.96 billion by 2032 and ADHD treatments anticipated to increase to $15.23 billion in the same timeframe, highlighting the demand for innovative and safer mental health solutions.
Get Free Real-Time Notifications for Any Stock
Analyst Views on ABVC
About ABVC
About the author
Plus Therapeutics Prices Public Offering, Raising $15 Million
- Financing Update: Plus Therapeutics announced the pricing of 39,473,684 units at $0.38 each, expecting to raise approximately $15 million, which will provide fresh capital to advance its precision diagnostics and radiopharmaceutical programs targeting central nervous system cancers.
- Market Performance: Connect Biopharma's stock rose 5.96% to $2.31 without any new news, reflecting ongoing investor interest in its lead candidate rademikibart's new mechanism of action data and strategic priorities for 2026.
- Sector Momentum: ABVC BioPharma's shares increased by 3.37% to $2.15, suggesting that investor interest may be driven by broader momentum in the biotech sector despite the absence of new corporate updates.
- Clinical Progress: Traws Pharma's stock rose 2.82% to $1.82 following its announcement of filing a U.S. IND application for tivoxavir marboxil, further supporting investor optimism around the company's pipeline.
ABVC BioPharma, Inc. (ABVC) Sees 103% Increase in Assets, Preparing for Phase III Trials of Depression Treatments
Overview of ABVC BioPharma: ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing botanically derived therapeutics for various medical conditions, including Major Depressive Disorder and oncology-related diseases.
Financial Performance and Pipeline Progress: The company reported significant financial growth, with a 103% increase in assets and upcoming Phase III trials for its leading drug candidates, while also noting that certain AI stocks may present better investment opportunities.
